A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

2期 已完成 NCT05039450

摘要

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.

Main: Change From Baseline in Fibrosis With no Worsening Steatohepatitis Assessed by NASH CRN System

Week 36 · Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
• Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
• Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
• Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
• Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
• Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

全部试验